Inotersen (sodium)

Inotersen (ISIS-420915) sodium is a 2′-O-methoxyethyl-modified antisense oligonucleotide. Inotersen sodium inhibits the production of transthyretin (TTR) protein by targeting the TTR RNA transcript and reduces the levels of the TTR transcript. Inotersen sodium can be used for the research of hereditary TTR amyloidosis polyneuropathy[1][2][3].

Product Specifications

CAS Number

[1432726-13-0]

Product Name Alternative

ISIS-420915 (sodium)

UNSPSC

12352208

Target

Transthyretin (TTR)

Type

Oligonucleotides

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/inotersen-sodium.html

Purity

96.44

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

[Inotersen(sodium)]

Molecular Formula

C230H299N69Na19O121P19S19

Molecular Weight

7183.08 (free acid)

References & Citations

[1]Ackermann EJ, et, al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid. 2016 Sep;23 (3) :148-157.|[2]Mathew V, et, al. Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Des Devel Ther. 2019 May 6;13:1515-1525.|[3]Benson MD, et, al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379 (1) :22-31.